ScreenerHero

GRI GRI Bio, Inc.

NAS · US · Healthcare · Biotechnology · gribio.com
1.850USD-2.63%Mkt Cap: 4.04M $P/E: —

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United …

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap4.04M USD
Enterprise Value-6.73M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-11.96M USD
Revenue/Share—
Last Price1.850 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees3
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.95
PEG—
EV/EBITDA0.69
EV/Revenue—
P/S—
P/B0.40
EPS (TTM)-14.71
EPS (Forward)-2.00
52W Range
1.3601% of range64.12
52W High64.12 USD
52W Low1.360 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-199.00%
ROA-137.96%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-10.19M USD
CapEx (TTM)3.00K USD
FCF Margin—
FCF Yield-162.86%
Net Debt-10.90M USD
Net Debt/EBITDA1.13
Balance Sheet
Debt/Equity0.01
Current Ratio10.30
Quick Ratio9.95
Book Value/Sh4.70 USD
Cash/Share5.01 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:28
Split DateJan 26, 2026
Analyst Consensus
Rating—
Target (Mean)18.50 USD
Upside (mean)+900.0%
Target Range10.00 USD – 27.00 USD
10.00+900.0% to mean27.00
# Analysts2
Ownership
Shares Out.2.19M
Float2.19M
Insiders0.38%
Institutions4.28%
Short Interest
Short Ratio0.2d
Short % Float5.36%
Short % Out.5.36%
Shares Short117.10K
Short (prev mo.)127.08K
Technical
SMA 501.843 (+0.4%)
SMA 2002.867 (-35.5%)
Beta-0.61
S&P 52W Chg16.45%
Avg Vol (30d)404.98K
Avg Vol (10d)65.66K
Technical Indicators
RSI (14)46.3
MACD0.0103
MACD Signal0.0393
MACD Hist.-0.0290
BB Upper2.146 USD
BB Middle1.958 USD
BB Lower1.771 USD
BB Width19.12%
ATR (14)0.1818 USD
Vol Ratio (20d)0.06x